Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

271.12USD
10:54am EDT
Price Change (% chg)

$1.06 (+0.39%)
Prev Close
$270.06
Open
$272.57
Day's High
$274.19
Day's Low
$267.81
Volume
37,776
Avg. Vol
226,595
52-wk High
$283.00
52-wk Low
$131.50

REGN.OQ

Chart for REGN.OQ

About

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST... (more)

Overall

Beta: 0.96
Market Cap (Mil.): $26,456.74
Shares Outstanding (Mil.): 97.97
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 36.51 47.13 37.76
EPS (TTM): 7.40 -- --
ROI: 51.25 -2.58 18.76
ROE: 87.68 -2.66 19.59
Search Stocks

UK cost agency recommends Bayer, Regeneron eye drug

LONDON, May 31 - Britain's healthcare cost watchdog NICE is recommending a new eye drug from Bayer and Regeneron, after a price discount was offered for its use on the state health service.

30 May 2013

Regeneron settles all pending litigation with Roche's Genentech

May 20 - Regeneron Pharmaceuticals Inc said it settled all pending litigation with Roche Holding AG's unit Genentech on the company's eye drug, Eylea, and cancer drug, Zaltrap.

20 May 2013

FEATURE-Fast climbing biotech Regeneron still has room to grow

* Shares jump five-fold in two years, market value $26 bln

07 May 2013

UPDATE 2-Regeneron raises Eylea sales view, shares hit all-time high

* Shares hit life-high of $270 (Adds comments from conference call, analyst comment)

03 May 2013

Regeneron raises 2013 Eylea sales view, profit beats Street

- Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as sales of its eye drug Eylea continued to gather pace, and the company raised its 2013 sales estimate for the drug.

03 May 2013

Regeneron raises 2013 Eylea sales view, profit beats Street

May 3 - Regeneron Pharmaceuticals Inc's first-quarter results beat analysts' estimates for the seventh straight quarter as the sales of its eye drug Eylea continued to gather pace, and the company raised its 2013 sales estimate for the drug.

03 May 2013

UPDATE 3-Allergan delays drug that would rival Regeneron's Eylea

May 1 - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands to gain from a lack of new competition.

01 May 2013

BRIEF-Regeneron Pharma shares resume trading, up 16 percent

NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares resume trading, up 16 percent * Shares as shares of Allergan slide after co says vision drug approval

01 May 2013

BRIEF-Regeneron Pharma shares halted, last up 14.3 pct

NEW YORK, May 1 - Regeneron Pharmaceuticals Inc : * Shares halted, last up 14.3 percent

01 May 2013

BRIEF-Regeneron Pharma shares up 2.8 pct after the bell

NEW YORK, April 24 - Regeneron Pharmaceuticals Inc : * Shares up 2.8 percent after the bell, to join S&P 500 next week

24 Apr 2013

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF66.60 +0.35
Pfizer Inc. (PFE.N) $29.18 -0.05
Bayer AG (BAYGn.DE) €89.07 +1.72
Bayer AG (BAYE.F) -- --
Onyx Pharmaceuticals, Inc. (ONXX.OQ) $133.50 +2.20
Abbott Laboratories (ABT.N) $36.92 +0.29
Sanofi SA (SASY.PA) €76.35 -3.82
Merck & Co., Inc. (MRK.N) $48.13 -0.04
Amgen, Inc. (AMGN.OQ) $109.04 +0.75
Roche Holding Ltd. (ROG.VX) CHF228.00 -3.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$472.00
Provider: Stock Traders Daily
$495.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks